DIFFERENTsIROVANNYY PODKhOD K VYBORU STARTOVOY TERAPII PRI KhOBL
- Autores: Tatarskiy A.R1, Kirillova D.A1
-
Afiliações:
- Edição: Nº 6-2 (2014)
- Páginas: 32-34
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286784
- ID: 286784
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Chronic obstructive pulmonary disease is a serious medical and social problem. Morbidity and mortality from chronic obstructive pulmonary disease do not tend to decrease. For the improvement of prognosis and quality of life of the individual patient, it is necessary to make the accurate diagnosis, evaluate the course and prognosis of the disease using an integrated approach, and find an individual treatment.
Texto integral
Bibliografia
- Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
- Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.) / Пер. с англ. под ред. А.С. Белевского. М., 2012. С. 12. Доступно на http://www.goldcopd.org
- Vestbo J., Anderson W., Coxson H.O., et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur. Respir. J. 2008; 31: 869-73.
- Agusti A., Calverely P., Celli B., et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010.
- Татарский А.Р. Принципы выбора препаратов для лечения хронической обструктивной болезни лёгких согласно новым международным клиническим рекомендациям. Пульмонология. 2013; 2: 89.
- Cazzola W., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31(2): 416.
- Mahler D.A. The effect of inhalated beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 10(Suppl. 6): 298.
- Bateman E.D. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004; 170(8): 836.
- Mahler D.A., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166(8): 1084.
- Vestbo J. New thinking and COPD. Ugeskr Laeger. 2003; 16(45): 4319.
- Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol TORCH Study Group. Eur. Respir. J. 2004; 24(2): 206.
- Calverley P.M., et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356(8): 775.
- Княжеская Н.П. Ингибиторы фосфодиэстеразы-4 - противовоспалительные препараты в лечении ХОБЛ. РМЖ. Болезни дыхательных путей. 2013; 29 (доступно на http://www.rmj.ru/articles_9010.htm)
- Celli B.R., Thomas N.E., Anderson J.A., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178(4): 332-38.
Arquivos suplementares
